Stalled Gene Therapy for Metabolic Disorder Licensed
The therapy, designed to treat urea cycle defects in children, finds new backing to continue development after a prior insolvency.
Updated on Oct. 27, 2026 in Biotech
Live Poll
Do you believe non-profit organizations should take over development of abandoned pharmaceutical programs?
Orphan Therapeutics Accelerator has licensed the gene therapy program OTXL-101 to treat ornithine transcarbamylase deficiency. The program, which targets patients aged 2 to 18, was reclaimed from UCL Ventures and the Children's Medical Research Institute after its previous sponsor became insolvent.
Why it matters
Ornithine transcarbamylase deficiency leads to toxic ammonia accumulation and life-threatening neurological complications, making this a critical effort to rescue shelved therapies. The accelerator utilizes a non-profit model to navigate rare disease development.
The therapy shows 17 months of durable response in a patient out of a planned cohort of 12. These results were observed over a two-and-a-half-year period of clinical evidence.
The players
Orphan Therapeutics Accelerator
A Cambridge-based non-profit developer focused on reviving shelved gene therapies for rare diseases.
UCL Ventures
The commercialization arm of University College London focused on translating research into clinical programs.
Children's Medical Research Institute
A Sydney-based research organization specializing in gene therapy and childhood disease mechanisms.
The details
OTXL-101 uses an adeno-associated virus (AAV) vector—a modified, harmless virus used as a delivery vehicle—to introduce a functional gene into the liver. This process aims to restore normal urea cycle activity, the metabolic pathway responsible for processing ammonia. The therapy has secured US and EU Orphan Drug Designations and a US Rare Pediatric Disease Designation.
Timeline
October 2023: Phase 1/2 HORACE trial initiated
2025: Data presented at ASGCT Annual Meeting
October 27, 2026: Licensing agreement announced
The Tech Race
This acquisition secures the future of the HORACE trial, which previously hit a roadblock due to sponsor insolvency. It positions the accelerator to advance this therapy toward potential regulatory approval and a Priority Review Voucher.
The therapy is intended for pediatric to adolescent patients aged 2 to 18 with ornithine transcarbamylase deficiency. Families should monitor progress on clinical trial sites, as the accelerator has not yet announced a timeline for resuming patient enrollment.
The takeaway
This development rescues a high-stakes gene therapy program from the brink of abandonment due to developer insolvency. Watch for future updates on the trial status and potential eligibility for a Priority Review Voucher upon successful completion.
Further reading
Explore ongoing Biotech developments in gene therapy and orphan drug research.
More information
Learn more about the program goals on the Orphan Therapeutics Accelerator corporate website.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you believe non-profit organizations should take over development of abandoned pharmaceutical programs?
